The Short Answer
KLOW is not a single peptide. It's a nickname used by sellers and forums for a blend of four research peptides in one vial: BPC-157, TB-500, GHK-Cu, and KPV. Drop the KPV and you have the three-peptide blend people call GLOW. Drop the GHK-Cu as well and you have the two-peptide Wolverine stack.
Three facts frame everything else on this page:
- No clinical trial has tested KLOW as a product. Everything written about "KLOW benefits" is borrowed from research on the individual components, most of it in animals or cells.
- None of the four ingredients is an FDA-approved drug for injection. Vials sold online are "research use only" products, not medicines.
- There is no evidence-based KLOW dose or schedule. This guide explains the label math people ask about, but it doesn't recommend an amount or a frequency. That decision belongs with a licensed clinician.
KLOW at a Glance
| What it is | A vendor-named blend of BPC-157 + TB-500 + GHK-Cu + KPV in one lyophilized vial |
| Marketed for | Injury recovery, joint and tendon pain, gut comfort, skin and collagen support |
| Human evidence for the blend | None published |
| FDA status | Not approved. All four components appear on FDA's list of bulk substances that may present significant safety risks in compounding |
| Ratios | Vary by seller. Read your own label |
| Related blends | GLOW (no KPV), Wolverine (BPC-157 + TB-500 only) |
What's in KLOW: The Four Ingredients
| Component | What it is | What the research mostly covers |
|---|---|---|
| BPC-157 | A synthetic 15-amino-acid peptide based on a sequence from gastric juice | Tendon, muscle, gut and blood-vessel repair, almost all in rats. A 2025 narrative review found only three small human pilot studies |
| TB-500 | A synthetic fragment marketed as related to thymosin beta-4 (Tβ4), a naturally occurring repair peptide | Cell migration, wound healing and tissue repair, mostly research on the parent Tβ4 rather than the fragment sold as TB-500 |
| GHK-Cu | A naturally occurring copper-binding tripeptide (glycyl-histidyl-lysine) | Skin, wound healing and gene-expression research; much of it is lab, animal or topical work, not injection |
| KPV | A tripeptide (lysine-proline-valine) derived from the end of alpha-MSH | Anti-inflammatory effects in cell and mouse colitis models via PepT1 uptake |
Two things get lost in forum summaries:
- TB-500 is not thymosin beta-4. Most of the impressive-sounding research is about the full Tβ4 protein, not the short synthetic fragment in a KLOW vial. They are not automatically interchangeable.
- GHK-Cu's strongest data is topical. Creams and serums for skin are where the human evidence sits. Injected GHK-Cu is a separate, less-studied route, and copper peptides can irritate injection sites.
For deeper reads: KPV peptide benefits, GHK-Cu guide, and the BPC-157 + TB-500 stacking guide.
What the Research Actually Shows
Read this before any "KLOW benefits" list online.
| Layer of evidence | What it can support | What it cannot |
|---|---|---|
| Component papers | Separate biology for BPC-157, thymosin beta-4, GHK-Cu and KPV | Anything about the four-way blend |
| Seller listings | Claimed milligrams per vial | Identity, purity or potency of what's in the vial |
| Community reports | What people say they noticed | Efficacy or safety |
- BPC-157: A 2025 narrative review from the University of Utah found only three human pilot studies (knee pain, interstitial cystitis, and an IV safety study) and concluded that rigorous, large-scale trials are lacking. The knee study was a retrospective chart review of 16 patients at one clinic with no control group.
- Thymosin beta-4: The 2012 review by Goldstein and colleagues describes Tβ4's regenerative properties and early clinical work on the full peptide. The fragment sold as TB-500 lacks strong human exposure data.
- GHK-Cu: Pickart and Margolina's 2018 review covers wound healing, skin remodeling and gene-expression changes, with most human data from topical products.
- KPV: Dalmasso and colleagues showed in 2008 that KPV reduced intestinal inflammation in mouse colitis models through the PepT1 transporter. That's a mouse gut model, not a human recovery study.
Animal and cell data can be real without telling you whether a blend works, or is safe, in people at the amounts sold online. If you want an honest comparison of the recovery blends, see best recovery peptide blends: KLOW vs GLOW.
KLOW vs GLOW vs Wolverine
| Blend | BPC-157 | TB-500 | GHK-Cu | KPV |
|---|---|---|---|---|
| Wolverine | ✓ | ✓ | ||
| GLOW | ✓ | ✓ | ✓ | |
| KLOW | ✓ | ✓ | ✓ | ✓ |
- KLOW vs GLOW: the only difference is KPV. Sellers position KLOW toward gut and inflammation stories and GLOW toward skin and collagen, but the component ratios differ from vendor to vendor, so the names describe a recipe, not a standard.
- KLOW vs Wolverine: Wolverine is the two-peptide base. Adding GHK-Cu and KPV adds variables, not proven extra benefit.
Each added peptide is one more thing you can't isolate if something goes wrong. If you react to a blend, you can't tell which component caused it without splitting the vials under clinician guidance.
Is KLOW Legal? FDA and Regulatory Status
- Not FDA-approved. No KLOW product, and none of its four components, is an approved injectable drug.
- On FDA's safety-risk list. FDA's list of bulk drug substances that may present significant safety risks in compounding names BPC-157, GHK-Cu (for injectable routes), KPV, and the thymosin beta-4 fragment known as TB-500. FDA cites immunogenicity concerns and gaps in human safety data. That is the opposite of an approval.
- July 2026 advisory vote. FDA's Pharmacy Compounding Advisory Committee recommended that BPC-157, KPV and TB-500 be considered for the 503A compounding bulks list. A committee recommendation is not FDA approval and does not by itself let a pharmacy compound these peptides. Our post-PCAC explainer walks through what has and hasn't changed.
- "Research use only" vials sold to consumers aren't legal drugs for human use. FDA's 2026 warning letters make clear that the label doesn't change that when a seller is marketing for human use.
- Athletes: check your sport's rules before using any peptide.
KLOW Label Math (Arithmetic, Not a Dose)
The most common search after "what is KLOW" is some version of "KLOW dosage chart." Here's the honest answer: a blend can't be split, so every draw contains all four peptides in the label's fixed ratio. The math below converts a label into milligrams per draw. It is not a recommended amount.
For a U-100 insulin syringe, 10 units = 0.1 mL, and:
mg of one component per 10 units = (mg of that component on the label ÷ mL of water added) × 0.1
Example label A (GHK-heavy write-ups)
BPC-157 10 mg + TB-500 10 mg + GHK-Cu 50 mg + KPV 10 mg (80 mg total)
| Water added | BPC-157 / 10 units | TB-500 / 10 units | GHK-Cu / 10 units | KPV / 10 units |
|---|---|---|---|---|
| 2 mL | 0.5 mg | 0.5 mg | 2.5 mg | 0.5 mg |
| 3 mL | 0.333 mg | 0.333 mg | 1.667 mg | 0.333 mg |
| 5 mL | 0.2 mg | 0.2 mg | 1.0 mg | 0.2 mg |
Example label B (even four-way, 40 mg total)
10 mg of each component
| Water added | Each component / 10 units |
|---|---|
| 2 mL | 0.5 mg |
| 3 mL | 0.333 mg |
| 5 mL | 0.2 mg |
Same "10 units," very different amounts once the label ratio changes. That is why KLOW dosage charts online contradict each other: they're built on different labels. Run your own label through the KLOW blend reconstitution calculator rather than trusting a screenshot.
